← Eichor
Study identifier: NCT06174506 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Role of hs Troponin I and NT-proBNP in Predicting Atrial Fibrillation in Patients With Permanent Pacemakers

Condition: Atrial Fibrillation  ·  Sponsor: University of Medicine and Pharmacy at Ho Chi Minh City

PhaseN/A
Planned participants300
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The goal of this clinical trial is to answer the research question whether hs Troponin I and NT-proBNP have a role in detecting atrial fibrillation in patients with pacemakers. Objectives of the study: 1. To survey some risk factors for atrial fibrillation in patients with permanent pacemakers. 2. To determine the role of hs Troponin I and NT-proBNP in predicting new-onset atrial fibrillation within follow-up time. 3. To build a model to predict the prognosis of atrial fibrillation based on the detected subclinical markers related to atrial fibrillation and classic cardiovascular risk factors.

This description comes directly from the study's public registry record.

Talk to the study team

Linh HK Duong, Master, MD  ·  + 84 0366698048  ·  khanhlinh175@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Cho Ray HospitalHo Chi Minh City, None Selected, VietnamRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06174506